{
    "General": {
        "Code": "P731",
        "Type": "Common Stock",
        "Name": "MEDEXUS PHARMACEUTIC.",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "CA58410Q2036",
        "LEI": null,
        "PrimaryTicker": "MDP.V",
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "March",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Drug Manufacturers-Specialty & Generic",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Pharmaceuticals",
        "GicSubIndustry": "Pharmaceuticals",
        "Description": "Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 98,
        "UpdatedAt": "2023-09-01"
    },
    "Highlights": {
        "MarketCapitalization": 38581516,
        "MarketCapitalizationMln": 38.5815,
        "EBITDA": 19026000,
        "PERatio": 13.5,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 1.121,
        "DividendShare": 0,
        "DividendYield": 0,
        "EarningsShare": 0.14,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2023-06-30",
        "ProfitMargin": 0.028,
        "OperatingMarginTTM": 0.1138,
        "ReturnOnAssetsTTM": 0.0547,
        "ReturnOnEquityTTM": 0.1623,
        "RevenueTTM": 116605000,
        "RevenuePerShareTTM": 5.817,
        "QuarterlyRevenueGrowthYOY": 0.369,
        "GrossProfitTTM": 65766000,
        "DilutedEpsTTM": 0.14,
        "QuarterlyEarningsGrowthYOY": 0
    },
    "Valuation": {
        "TrailingPE": 13.5,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": 100009360,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 20413500,
        "SharesFloat": 17078754,
        "PercentInsiders": 11.941,
        "PercentInstitutions": 5.535,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 1.7574,
        "52WeekHigh": 2.22,
        "52WeekLow": 0.67,
        "50DayMA": 1.5147,
        "200DayMA": 1.2366,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0,
        "ForwardAnnualDividendYield": 0,
        "PayoutRatio": 0,
        "DividendDate": null,
        "ExDividendDate": null,
        "LastSplitFactor": "1:15",
        "LastSplitDate": "2018-12-19",
        "NumberDividendsByYear": {}
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}